Micron to Invest $250 Billion in U.S. by 2035, Targeting 40% Domestic DRAM Production
The company poured the first concrete at its Clay, New York site, marking the start of the largest semiconductor project in U.S. history.
/ 220 items
#andre↓
Starbucks Builds In-House AI Tools to Cut Reliance on Microsoft, IBM, and Oracle
Starbucks aims to slash $400M in annual software spend by building its own AI tools, challenging Microsoft Dynamics, IBM TRIRIGA, and Oracle Simphony.
Wainua Trial Setback Sends Ionis Plunging and Drags Down AstraZeneca
AstraZeneca and Ionis’s Wainua missed its primary endpoint in the Phase 3 ATTR-CM trial, while competitors Alnylam and BridgeBio surged.
Wolfe Research Upgrades Sarepta to Outperform as DM1 and FSHD Catalysts Approach
With key MAD data for DM1 and FSHD siRNA programs expected in H2 2026, SRPT stock shows strong growth potential.
Prime Medicine Wins Arbitration Dispute with Beam Therapeutics, Clears Path for PM647
Prime Medicine secures positive arbitration ruling against Beam Therapeutics: no damages owed for PM647 in AATD. IND/CTA filing planned for Q3 2026, first clinical data in 2027.
Raymond James Upgrades Tvardi Therapeutics to Outperform, Sets $10 Target on Strong TTI-109 Data
Tvardi’s new drug TTI-109 showed strong early results, fewer side effects, and potential in autoimmune diseases, boosting investor confidence.